For example, a combinatorial therapy with MAPK-signaling inhibitors and histone-deacetylase inhibitors showed a synergistic effect in reexpressing the NIS gene and in recovering the radioiodine trapping in BRAFV600E thyroid-cancer cell lines (62). Here, SLC5A5 is linked to thyroid gland carcinoma.